CXG 87
Alternative Names: budesonide/formoterol dry powder inhalation - Hangzhou Chance Pharmaceutical; CXG-87Latest Information Update: 14 May 2026
At a glance
- Originator Hangzhou Chance Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Asthma
- Phase III Chronic obstructive pulmonary disease
Most Recent Events
- 07 May 2026 Preregistration for Asthma (Combination therapy) in China (Inhalation)
- 07 May 2026 Efficacy and adverse events data from phase III trial in Asthma released by Chance Pharmaceuticals
- 07 May 2026 Hangzhou Chance Pharmaceuticals completes the phase III trial in Asthma (Combination therapy) in China (Inhalation) (CTR20250298)